Market Overview - On September 2, the Jiangsu state-owned enterprise reform sector fell by 0.85% compared to the previous trading day, with Lianhuan Pharmaceutical leading the decline [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] Stock Performance - Notable gainers in the Jiangsu state-owned enterprise reform sector included: - Huami Environmental Energy (600475) with a closing price of 23.86, up 10.00% [1] - Zhongsheng High-Tech (002778) with a closing price of 20.94, up 5.23% [1] - Nanjing Port (002040) with a closing price of 10.03, up 3.62% [1] - Major decliners included: - Lianhuan Pharmaceutical (600513) with a closing price of 21.96, down 6.63% [2] - Tongxingbao (301339) with a closing price of 16.73, down 4.35% [2] - Nanjing Chemical Fiber (600889) with a closing price of 15.16, down 4.29% [2] Capital Flow - The Jiangsu state-owned enterprise reform sector experienced a net outflow of 720 million yuan from institutional investors, while retail investors saw a net inflow of 409 million yuan [2][3] - The capital flow for specific stocks showed: - Huami Environmental Energy (600475) had a net inflow of 1.421 billion yuan from institutional investors [3] - Jiangsu Jinzhu (002091) had a net inflow of 12.13 million yuan from institutional investors [3] - Nanjing Travel (600250) had a net inflow of 10.72 million yuan from institutional investors [3]

南京医药股份有限公司 关于持股 5%以上股东间接权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： Alliance Healthcare Asia Pacific Limited（以下简称"Alliance Healthcare"） 直接持有南京医药股份有限公司（以下简称"公司"）144,557,431 股股份，占公 司总股本的 11.04%。本次权益变动系 Alliance Healthcare 的间接股东发生变化所 致。 本次权益变动前后，Alliance Healthcare持有的公司股份数额未发生变化。 本次权益变动前后，公司控股股东持股数额、比例未发生变化，公司控 股股东及实际控制人均未发生变化。 证券代码：600713 证券简称：南京医药 编号：ls2025-115 债券代码：110098 债券简称：南药转债 本次权益变动后，Alliance Healthcare 由合并重组完成后的主体 BSI 间接控 制，股权结构如下图所示： 本次权益变动前后，Alliance Healthc ...

证券代码：600713 证券简称：南京医药 编号：ls2025-114 使用部分暂时闲置募集资金进行现金管理到期赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 现金管理受托方：招商银行股份有限公司（以下简称"招商银行"） ? 本次现金管理金额：9,000万元（人民币，下同） ? 现金管理产品名称：南京医药股份有限公司（以下简称"公司"）子公 司福建同春药业股份有限公司（以下简称"福建同春"）本次使用部分暂时闲置 募集资金 9,000 万元购买招商银行点金系列看涨两层区间 91 天结构性存款。 ? 履行的审议程序：公司于2025年1月20-22日召开了第九届董事会临时会 议及第九届监事会临时会议，审议通过了《关于公司及子公司使用部分暂时闲置 募集资金进行现金管理的议案》，同意公司及子公司使用不超过7亿元（含本数） 暂时闲置募集资金进行现金管理，投资的产品品种为安全性较高、流动性较好、 风险较低的保本型理财产品。使用期限自公司董事会审议通过之日起12个月内有 效，上述额度在使用期 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.04% on September 1, with Nanjing Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Notable gainers included: - First Pharmaceutical (600833) with a closing price of 14.59, up 10.03% on a trading volume of 243,000 shares and a transaction value of 344 million [1] - Yingte Group (000411) closed at 12.30, up 5.67% with a trading volume of 254,500 shares and a transaction value of 304 million [1] - Key decliners included: - Nanjing Pharmaceutical (600713) closed at 5.00, down 3.10% with a trading volume of 475,300 shares and a transaction value of 238 million [2] - Baiyang Pharmaceutical (301015) closed at 25.92, down 1.82% with a trading volume of 90,800 shares and a transaction value of 236 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 163 million from institutional investors, while retail investors experienced a net inflow of 24.07 million [2] - The main capital inflow was observed in: - First Pharmaceutical with a net inflow of 47.35 million from institutional investors [3] - Nanjing Pharmaceutical with a net inflow of 30.12 million from institutional investors [3] Individual Stock Capital Flow - First Pharmaceutical had a net inflow of 47.35 million from institutional investors, while retail investors had a net outflow of 10.93 million [3] - Nanjing Pharmaceutical saw a net inflow of 30.12 million from institutional investors, but a significant net outflow of 63.89 million from retail investors [3]

证券代码：600713 证券简称：南京医药 公告编号：ls2025-113 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、回购股份的基本情况 2025 年 3 月 14 日，南京医药股份有限公司（以下简称"公司"）召开第九届 董事会 2025 年第一次临时会议，审议通过了《关于以集中竞价交易方式回购公司 股份方案的议案》，同意公司以自有资金或自筹资金通过集中竞价交易方式回购公 司股份，用于实施 2025 年限制性股票激励计划。本次回购的资金总额不低于人民 币 7,000 万元（含）且不超过人民币 13,158 万元（含）；回购价格不超过人民币 7.31 元/股（含）；回购期限为自公司董事会审议通过本次回购股份方案之日起不超过 12 个月。详情请见公司于 2025 年 3 月 15 日对外披露的编号为 ls2025-021 之《南 京医药股份有限公司关于以集中竞价交易方式回购股份方案的公告》，以及 ...

债券代码：110098 债券简称：南药转债 南京医药股份有限公司关于公司及子公司 使用部分暂时闲置募集资金进行现金管理到期赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理产品名称：南京医药股份有限公司（以下简称"公司"）子公 司福建同春药业股份有限公司（以下简称"福建同春"）本次使用部分暂时闲置 募集资金 9,000 万元购买招商银行点金系列看涨两层区间 91 天结构性存款。 | | | 履行的审议程序：公司于2025年1月20-22日召开了第九届董事会临时会 议及第九届监事会临时会议，审议通过了《关于公司及子公司使用部分暂时闲置 募集资金进行现金管理的议案》，同意公司及子公司使用不超过7亿元（含本数） 暂时闲置募集资金进行现金管理，投资的产品品种为安全性较高、流动性较好、 风险较低的保本型理财产品。使用期限自公司董事会审议通过之日起12个月内有 效，上述额度在使用期限内可以滚动使用，到期后归还至募集资金专户。 特别风险提示：尽管公司购买的结构性存款安全性较高、流动性较好 ...

Financial Performance - Nanjing Pharmaceutical reported a total revenue of 27.967 billion yuan for the first half of 2025, an increase of 2.7% year-on-year [1] - The net profit attributable to shareholders was 291 million yuan, a decrease of 6.44% compared to the previous year [1] - In Q2 2025, total revenue reached 13.721 billion yuan, up 3.32% year-on-year, while net profit dropped by 25.17% to 114 million yuan [1] Profitability Metrics - The gross margin was 5.91%, down 4.08% year-on-year, and the net margin was 1.36%, a decline of 6.99% [1] - The total of selling, administrative, and financial expenses was 1.007 billion yuan, accounting for 3.6% of revenue, a decrease of 5.4% year-on-year [1] - Earnings per share (EPS) decreased by 7.5% to 0.22 yuan, while operating cash flow per share was -3.08 yuan, down 71.41% [1] Asset and Debt Management - Cash and cash equivalents decreased by 6.34% to 2.306 billion yuan, while accounts receivable increased by 16.21% to 16.948 billion yuan [1] - Interest-bearing liabilities decreased by 20.97% to 8.231 billion yuan, indicating improved debt management [1] - The company's return on invested capital (ROIC) was 7.08%, with a historical median of 8.11%, suggesting average capital returns [1][2] Business Model Insights - The company's performance is primarily driven by marketing efforts, necessitating a deeper analysis of the underlying factors [2] - The cash flow situation is concerning, with cash assets only 7.19% of total assets and 18.3% of current liabilities [3] - The accounts receivable to profit ratio reached 2970.15%, indicating potential issues with cash collection [3]

Core Viewpoint - The company has released its 2025 semi-annual report, which includes details on financial performance, profit distribution, and the management of raised funds [3][9][30]. Group 1: Company Overview - The company is named Nanjing Pharmaceutical Co., Ltd., with stock code 600713 and bond code 110098 [5]. - The board of directors and supervisory board confirm the authenticity and completeness of the report [1][28]. Group 2: Financial Data - The company did not distribute profits during the reporting period, but plans to distribute a cash dividend of 1.70 yuan per 10 shares, totaling approximately 222.47 million yuan [3]. - The total amount raised from the issuance of convertible bonds was approximately 1.08 billion yuan, with a net amount of about 1.07 billion yuan after deducting issuance costs [13]. Group 3: Fund Management - As of June 30, 2025, the balance of the raised funds was approximately 124.10 million yuan [14]. - The company has established special accounts for the management of raised funds, ensuring compliance with relevant regulations [15]. - The company has not used idle raised funds to temporarily supplement working capital [18]. Group 4: Board and Supervisory Meetings - The board of directors held its third meeting on August 28, 2025, where all proposals were approved unanimously [8][9]. - The supervisory board also approved the semi-annual report and the special report on the management of raised funds, with no dissenting votes [30][31].

证券日报网讯 8月29日晚间，南京医药发布公告称，2025年半年度公司实现营业收入27，967，411， 701.62元，同比增长2.70%；归属于上市公司股东的净利润为291，276，712.36元，同比下降6.44%。 （编辑 何成浩） ...

（文章来源：证券日报） 证券日报网讯 8月29日晚间，南京医药发布公告称，公司第十届董事会第三次会议审议通过了《南京医 药股份有限公司2025年半年度报告》及其摘要等多项议案。 ...